Downregulation of miR-222-3p Reverses Doxorubicin-Resistance in LoVo Cells Through Upregulating Forkhead Box Protein P2 (FOXP2) Protein

BACKGROUND: Doxorubicin (DOX) is a potent chemotherapeutic agent used to treat colon cancer. Despite impressive initial clinical responses, drug resistance has dramatically compromised the effectiveness of DOX. However, the underlying mechanisms of chemotherapeutic resistance in colon cancer remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huaiming, Deng, Zhenwei, Chen, Xinhua, Cai, Jian, Ma, Tenghui, Zhong, Qinghua, Li, Ruiping, Li, Libo, Lin, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Lab/In Vitro Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442496/
https://www.ncbi.nlm.nih.gov/pubmed/30904920
http://dx.doi.org/10.12659/MSM.913325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442496/
https://www.ncbi.nlm.nih.gov/pubmed/30904920
http://dx.doi.org/10.12659/MSM.913325

Ejemplares similares